Full text is available at the source.
Abstract
Concerns regarding psychiatric adverse events, particularly suicidality, are associated with the use of GLP-1 receptor agonists in adolescents.
- GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists are commonly prescribed for adolescent obesity.
- There is increasing usage of these medications among this population.
- Psychiatric adverse events, including suicidality, remain a significant concern.
- Monitoring for these adverse events is crucial as their prevalence may impact treatment decisions.
Simplified